IFNA1 and myeloid sarcoma: In light of the recent successes reported with B cell depleting strategies in MS patients6,7, in combination with the inability of IFN to dampen EAE progression in mice in the absence of B cells20, we decided to compare targeting of IFN activity towards plasmacytoid DC (pDC) and/or conventional type 1 DC (cDC1) with B cell targeting.